Transcriptional activator which probably serves as a general switch factor for erythroid development. It binds to DNA sites with the consensus sequence [AT]GATA[AG] within regulatory regions of globin genes and of other genes expressed in erythroid cells. May form homodimers or heterodimers with other isoforms. Interacts (via the N-terminal zinc finger) with ZFPM1. Interacts with GFI1B. Interacts with PIAS4; the interaction enhances sumoylation and represses the transactivational activity in a sumoylation-independent manner. Interacts with LMCD1. Interacts with CREBBP; the interaction stimulates acetylation and transcriptional activity in vivo. Interacts with EP300. Erythrocytes. 3 isoforms of the human protein are produced by alternative splicing. Note: This description may include information from UniProtKB.
Molecular Function: protein binding; DNA binding; zinc ion binding; chromatin DNA binding; sequence-specific DNA binding; p53 binding; DNA bending activity; transcription factor activity
Biological Process: transcription from RNA polymerase II promoter; tissue development; erythrocyte development; in utero embryonic development; megakaryocyte differentiation; embryonic hemopoiesis; positive regulation of transcription, DNA-dependent; positive regulation of erythrocyte differentiation; heart development; eosinophil differentiation; male gonad development; negative regulation of transcription from RNA polymerase II promoter; negative regulation of cell proliferation; negative regulation of bone mineralization; positive regulation of peptidyl-tyrosine phosphorylation; organ morphogenesis; cell-cell signaling; gut development; positive regulation of osteoblast proliferation; erythrocyte differentiation; positive regulation of transcription from RNA polymerase II promoter; platelet formation; blood coagulation; basophil differentiation; negative regulation of apoptosis
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.